Oncogenic KIT mutations in different exons lead to specific changes in melanocyte phospho-proteome

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• Proto-oncogene c-KIT (KIT) mutations are implicated in various cancers.
• The location of KIT mutations varies significantly across different cancer types.
• Targeted KIT inhibitors have shown limited efficacy in treating KIT-mutant cancers.

Purpose of the Study:

• To investigate the functional impact of specific KIT mutations (KIT(559), KIT(642), KIT(816)) in primary human melanocytes (PHM).
• To identify kinases differentially activated by distinct KIT mutations.
• To explore novel therapeutic targets based on mutation-specific kinase activation.

Main Methods:

• Site-directed mutagenesis was used to introduce specific KIT mutations into PHM.
• Canonical KIT-signaling pathways were analyzed using immunoblotting.
• Stable isotope labeling by amino acids in cell culture (SILAC) and kinase prediction models identified activated kinases.
• Phosphorylation levels of selected substrates were analyzed for validation.

Main Results:

• KIT(559) and KIT(642) mutations led to increased activity of Casein Kinase 1 epsilon (CK1 ε) and delta (δ).
• KIT(816) mutations resulted in heightened activity of PAK Serine/Threonine Kinase 4 (PAK4).
• Distinct KIT mutations activate specific downstream kinases, altering the phospho-proteome.

Conclusions:

• Specific KIT mutations differentially activate distinct kinases (CK1 ε/δ vs. PAK4).
• These findings provide insights into mutation-specific signaling pathways.
• Identifying these activated kinases offers potential new therapeutic targets for KIT-mutant cancers.